
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
MacroChem Corporation has formed a scientific advisory board to help the company in evaluating new applications for its current transdermal technologies.